| Title |
Applications of pharmacogenomics in regulatory science: a product life cycle review
|
|---|---|
| Published in |
The Pharmacogenomics Journal, December 2017
|
| DOI | 10.1038/tpj.2017.47 |
| Pubmed ID | |
| Authors |
W C Tan-Koi, P C Leow, Y Y Teo |
| Abstract |
With rapid developments of pharmacogenomics (PGx) and regulatory science, it is important to understand the current PGx integration in product life cycle, impact on clinical practice thus far and opportunities ahead. We conducted a cross-sectional review on PGx-related regulatory documents and implementation guidelines in the United States and Europe. Our review found that although PGx-related guidance in both markets span across the entire product life cycle, the scope of implementation guidelines varies across two continents. Approximately one-third of Food and Drug Administration (FDA)-approved drugs with PGx information in drug labels and half of the European labels posted on PharmGKB website contain recommendations on genetic testing. The drugs affected 19 and 15 World Health Organization Anatomical Therapeutic Chemical drug classes (fourth level) in the United States and Europe, respectively, with protein kinase inhibitors (13 drugs in the United States and 16 drugs in Europe) being most prevalent. Topics of emerging interest were novel technologies, adaptive design in clinical trial and sample collection.The Pharmacogenomics Journal advance online publication, 5 December 2017; doi:10.1038/tpj.2017.47. |
X Demographics
The data shown below were collected from the profiles of 3 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United Kingdom | 1 | 33% |
| Indonesia | 1 | 33% |
| United States | 1 | 33% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 3 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 32 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 32 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 6 | 19% |
| Student > Bachelor | 4 | 13% |
| Student > Master | 3 | 9% |
| Student > Ph. D. Student | 3 | 9% |
| Student > Postgraduate | 2 | 6% |
| Other | 7 | 22% |
| Unknown | 7 | 22% |
| Readers by discipline | Count | As % |
|---|---|---|
| Pharmacology, Toxicology and Pharmaceutical Science | 6 | 19% |
| Biochemistry, Genetics and Molecular Biology | 4 | 13% |
| Social Sciences | 2 | 6% |
| Nursing and Health Professions | 2 | 6% |
| Medicine and Dentistry | 2 | 6% |
| Other | 6 | 19% |
| Unknown | 10 | 31% |
Attention Score in Context
This research output has an Altmetric Attention Score of 2. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 11 December 2017.
All research outputs
#14,608,019
of 24,003,070 outputs
Outputs from The Pharmacogenomics Journal
#522
of 854 outputs
Outputs of similar age
#231,542
of 446,420 outputs
Outputs of similar age from The Pharmacogenomics Journal
#10
of 20 outputs
Altmetric has tracked 24,003,070 research outputs across all sources so far. This one is in the 38th percentile – i.e., 38% of other outputs scored the same or lower than it.
So far Altmetric has tracked 854 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 5.3. This one is in the 38th percentile – i.e., 38% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 446,420 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 47th percentile – i.e., 47% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 20 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 50% of its contemporaries.